2006
DOI: 10.1055/s-2006-927266
|View full text |Cite
|
Sign up to set email alerts
|

Vergleichende Studie zur Therapie des Trockenen Auges bedingt durch Lipidphasenstörungen mit lipidhaltigen Tränenpräparaten

Abstract: The treatment with phospholipids liposomes shows statistically significant clinical advantages and proves to be favourably and explicitly superior compared to the conventional standard treatment all in all.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
16
0
3

Year Published

2010
2010
2024
2024

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 45 publications
(21 citation statements)
references
References 50 publications
2
16
0
3
Order By: Relevance
“…Our results are in good agreement with the results of Korb and others [11][12][13][14][15][16][17] that artificial tears containing phosphatidylcholine and other phospholipids strongly increase the thickness and the non-invasive break-up time of TF in vivo.…”
Section: Discussionsupporting
confidence: 92%
See 1 more Smart Citation
“…Our results are in good agreement with the results of Korb and others [11][12][13][14][15][16][17] that artificial tears containing phosphatidylcholine and other phospholipids strongly increase the thickness and the non-invasive break-up time of TF in vivo.…”
Section: Discussionsupporting
confidence: 92%
“…At present they are used as compounds of artificial tears (Tears Again, Soothe, Refresh Dry Eye Therapy, FreshKote, Refresh Endura) targeted to replenish the TF lipid layer of patients with Dry Eye Syndrome. Although the number of lipid-containing artificial tears on the market still remains relatively limited, in vivo studies demonstrated that formulations containing phospholipids and other PLs significantly increase the non-invasive break-up time of TF in laboratory animals and humans [11][12][13][14][15][16][17].…”
Section: Introductionmentioning
confidence: 99%
“…Similar to the findings by Böhm et al [6], the safety and tolerability of the treatment investigated here can be assessed as good, since no treatment-related adverse events or serious adverse events occurred. These results are consistent with those from previous studies evaluating the effect of LS for dry eye [8, 10] and with findings from studies assessing liposomal nasal spray [13, 15]. …”
Section: Discussionsupporting
confidence: 92%
“…The results of the patients’ perception of the treatment are comparable to those reported in studies exploring the application of liposomes for dry eye and in studies assessing liposomal nasal spray for treating seasonal allergic rhinitis. Subjective improvement of symptoms was observed in these studies [6-8, 11, 14]. For example, according to Lee et al [11], 72% of patients indicated noticeable relief of dry eye symptoms after the application of LS.…”
Section: Discussionmentioning
confidence: 97%
“…At present they are used as compounds of artificial tears (Tears Again, Soothe, Refresh Dry Eye Therapy, FreshKote, Refresh Endura) targeted to replenish the TF lipid layer of patients with Dry Eye Syndrome. Although the number of lipid-containing artificial tears on the market still remains relatively limited, in vivo studies demonstrated that formulations containing phospholipids and other PLs significantly increase the non-invasive break-up time of TF in laboratory animals and humans (4,10,11,12,13,14,21).…”
Section: Introductionmentioning
confidence: 99%